Table 1.
Cell lines used in screen.
| Cell line | Tissue of origin | Cells/well (384-well plate) | Population doubling time (h) | Growth Media during drug screening | Term Accession Number | Term Source REF |
|---|---|---|---|---|---|---|
| A498 | kidney cancer | 972 | 66.8 | RPMI 1640 10%FBS | BTO:0003769 | BTO |
| AGS | gastric adenocarcinoma | 800 | 20 | HAMS’s F12 5%FBS | BTO:0001007 | BTO |
| COLO 205 | colorectal cancer | 3000 | 23.8 | RPMI 1640 10%FBS | BTO:0000179 | BTO |
| DU-145 | prostate cancer | 2100 | 32.3 | RPMI 1640 10%FBS | BTO:0001332 | BTO |
| MDA-MB-468 | breast cancer | 8100 | 62 | RPMI 1640 5%FBS | BTO:0001570 | BTO |
| SF-295 | glioblastoma | 1050 | 29.5 | RPMI 1640 10%FBS | BTO:0004213 | BTO |
| SW-620 | colorectal cancer | 3750 | 20.4 | RPMI 1640 10%FBS | BTO:0000675 | BTO |
| UACC-62 | melanoma | 945 | 31.3 | RPMI 1640 10%FBS | BTO:0004152 | BTO |
Cell line density and growth media used are indicated. All media were supplemented with L-glutamine and penicillin-streptomycin. Population doubling time as annotated by provider. Cell lines are identified by BRENDA tissue/enzyme source (BTO, Version: 2016-05-05).